In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report). The company’s ...

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

Auburn remained in a tie for first place in the Sangamo Conference and extended its current win streak to 12 with hard-fought wins over Riverton (58-44) and Athens (68-52) last week. The final scores ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...

The Paxton-Buckley-Loda varsity girls basketball team won 53-36 over Riverton in the Illini Prairie/Sangamo Conference Shootout on Saturday. Tanner Graham finished with 14 points and would be named ...

Auburn used a big offensive night from Cooper Carter and another suffocating defensive effort to easily dispatch Stanford Olympia 61-23 in the Sangamo Conference opener Friday at Doglio Gym. Playing ...

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO – Free Report) in a research note ...

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) have been assigned a consensus recommendation of ...

Analysts have recently evaluated Sangamo Therapeutics and provided 12-month price targets. The average target is $8.09, accompanied by a high estimate of $10.00 and a low estimate of $2.00. Surpassing ...